SCHEDULE 13G/A: Biotechnology Value Fund Group Discloses 9.99% Stake in Cidara Therapeutics

A group of investment funds led by Biotechnology Value Fund, L.P. has filed an amended Schedule 13G, disclosing a combined beneficial ownership of 9.99% in Cidara Therapeutics, Inc. as of March 31, 2025.

Summary

• As of March 31, 2025, the Reporting Persons, including Biotechnology Value Fund, L.P. (BVF), Biotechnology Value Fund II, L.P. (BVF2), and Biotechnology Value Trading Fund OS LP, along with a Partners managed account, collectively beneficially owned 1,252,441 shares of Cidara Therapeutics, Inc. Common Stock.
• This aggregate ownership represents 9.99% of the outstanding shares of Cidara Therapeutics, Inc.
• Individually, BVF beneficially owned 715,842 shares (5.8%), BVF2 beneficially owned 463,146 shares (3.8%), and Biotechnology Value Trading Fund OS LP beneficially owned 53,919 shares (0.4%).
• The holdings include 280,869 Pre-Funded Warrants, exercisable at $0.0001 per share, which do not expire and are not currently limited by the 9.99% beneficial ownership blocker.
• The group also holds 975,208 shares of Series X convertible preferred stock, convertible into 487,604 common shares (0.5 shares per preferred share), though conversion is limited to 46,930 shares due to a 9.99% beneficial ownership cap.
• Additionally, 14,857 shares of Series A convertible preferred stock are held, convertible into 1,039,990 common shares (70 shares per preferred share), but conversion and voting of all Series A Preferred Stock are currently prohibited by a 9.99% beneficial ownership limitation.
• The total number of outstanding shares used for percentage calculation was 12,209,150 as of March 31, 2025, as disclosed in the Issuer's Form S-3 filed on May 8, 2025, plus applicable underlying shares from warrants and preferred stock.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the company's performance or outlook.

Risks

• The Pre-Funded Warrants Blocker prevents the exercise of Pre-Funded Warrants if the holder's beneficial ownership would exceed 9.99% of outstanding shares, although this limit did not apply to the Reporting Persons' holdings as of March 31, 2025.
• The Series X Conversion Limitation restricts the conversion of Series X Preferred Stock if beneficial ownership would exceed 9.99%, limiting the Reporting Persons to converting only 46,930 shares out of 487,604 underlying shares as of March 31, 2025.
• The Series A Conversion Limitation prohibits the conversion and voting of Series A Preferred Stock if beneficial ownership would exceed 9.99%, effectively preventing the conversion and voting of all Series A Preferred Stock held by the Reporting Persons as of March 31, 2025.

Future Outlook

This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or operations.

Industry Context

This filing is a standard disclosure of significant ownership by an investment fund group in a biotechnology company. It reflects an investment position rather than operational or strategic industry trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, which can influence market perception and trading activity.

Key Dates

Keywords

Cidara Therapeutics, Biotechnology Value Fund, SEC filing, Schedule 13G, Beneficial Ownership, Common Stock, Preferred Stock, Pre-Funded Warrants, Biotechnology, Investment Fund